Compare peptides
Put two entries side by side — evidence, mechanism, risks, and community claims.
PE-22-28 (Spadin Analog)
Preclinical
Research chemical
Summary
Synthetic heptapeptide optimized from the natural sortilin-derived peptide spadin. Potent selective inhibitor of the TREK-1 (KCNK2) two-pore-domain potassium channel with preclinical antidepressant and neuroplasticity signals.
Categories
Cognitive & Nootropic
Mechanism
Selectively blocks TREK-1 (KCNK2) with reported IC50 near 0.12 nM — roughly 300-fold more potent than parent spadin. TREK-1 blockade increases excitability of dorsal-raphe serotonergic neurons, elevates BDNF, phosphorylates CREB, and induces hippocampal neurogenesis within ~4 days in mouse models. Duration of antidepressant-like behavior reported up to ~23 hours in key characterization work.
Half-life
Short plasma; behavioral effects longer in rodents (~hours to a day)
Routes
Subcutaneous injection; Intranasal
Legal / access
Research chemical; not an approved antidepressant or nootropic drug.
Key risks
- Unknown human adverse-effect profile
- Theoretical cardiac TREK-1 expression concerns uncharacterized for this peptide
- Injection or nasal irritation
Common claims
- Fast mood support
- Neuroplasticity / focus
- Alternative to classic SSRI pathways (preclinical only)
Select peptide B